Q4 FY26 results analysis · May 26, 2026

Bayer CropScience Ltd Q4 FY26 Results Analysis: Margin Expands 280 bps, Material Costs Plunge 12%

+21.4%PAT year on year, Rs. 689.20 Cr
Cofacto ResearchPublished May 26, 20262 min readPositive read
Quick summary

Bayer CropScience Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 5,675.00 Cr (+3.70% YoY) and PAT growth of +21.40% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 26, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 5,675.00 Cr (+3.70% YoY)
PAT (Q4)Rs. 689.20 Cr (+21.40% YoY)
EBITDA margin15.40% (+280 bps YoY)
EPS (Q4)Rs. 153.35 (+21.30% YoY)
Market capRs. 19,730.05 Cr
CMPRs. 4,393.00

Quarter Snapshot

FY26 showed margin expansion (280 bps) and strong cash conversion despite moderate revenue growth of 3.7%. Cost management was excellent with material costs declining 12.1%, but trade receivables growing 17.2% warrants monitoring. No specific India guidance was provided against which to assess beats.

Key Investment Insights

Key Positives

  • FY26 EBITDA margin expanded 280 bps YoY to 15.4% from 12.6%, driven by 12.1% reduction in material costs and 2.6% cut in employee expenses.
  • FY26 PAT grew 21.4% YoY to Rs.6,892M on revenue growth of 3.7%, demonstrating operating leverage.
  • FY26 operating cash flow of Rs.10,785M was 1.56x PAT, indicating high earnings quality.
  • Working capital swung to a cash release of Rs.3,006M in FY26 from a cash use of Rs.3,651M in FY25.
  • DEKALB corn retained #1 market position for the 3rd consecutive year.
  • ROE improved 370 bps YoY to 23.6% in FY26.

Risk Factors

  • Trade receivables grew 17.2% YoY in FY26, far outpacing revenue growth of 3.7%, signaling potential collection pressure.
  • Revenue growth moderated to 3.7% in FY26 from 7% in FY25.
  • Three regulatory penalty orders totaling Rs.41.86M were received in Q4 FY26 for GST/E-way bill compliance issues.
  • The quarterly EBITDA margin of 18.4% in Q4 was partly boosted by inventory capitalization of Rs.3,677M, which may not recur.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.